Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

own in previous studies that the dose of M6G required to provide analgesia immediately after surgery is three times that of morphine. In accordance with this, the M6G022 trial was designed such that M6G was available in a 3:1 ratio to morphine during the titration to comfort phase. Thereafter pain relief was provided using patient controlled analgesia (PCA) in a dose ratio of 2:1 (M6G:morphine). The secondary data announced today demonstrated again that in the initial phase after surgery the dose of M6G required to titrate patients to comfort was 3 times that required for morphine on a weight basis. However, during the prolonged PCA phase, the ratio was lower (0-24 hours 1.6:1; 24-48 hours 1.4:1). This shows that patients in the M6G group made less demands for pain relief after titration to comfort, as assessed by presses on the PCA button. These data support the hypothesis that M6G has a longer duration of analgesic action than morphine.

Sedation/safety

The M6G022 data shows that M6G patients experience lower levels of sedation compared to those on morphine for up to 48 hours. This is another advantage of M6G that has been indicated from previous clinical data and adds to the considerable package of potential benefits to patients and clinicians. The M6G patients also showed no adverse cardiovascular effects which again supports CeNeS claims that M6G has a very good safety profile.

Partnering strategy

There is a clear need for new drugs that can improve the quality of pain management currently given to patients by standard morphine regimens across the world and M6G is well positioned to address that market. Since the announcement of the successful data last week significant interest has been expressed by Pharma companies in reviewing the large M6G data package that CeNeS has assembled. CeNeS is confident that agreements can be finalised with partner(s) based on the existing set of clinical trial data. Concluding these deals will generate
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:9/17/2014)... MARINA DEL REY, Calif. , Sept. 17, ... launch of the Prostate Vanguard, an awareness campaign to ... replace multiple rectal needle biopsies of the prostate. ... of the prostate gland through the rectum. Multi-parametric MRI ... for diagnosing clinically-significant prostate cancer (CSPC). Men need ...
(Date:9/17/2014)... 17, 2014 ACIST Medical Systems, Inc., a ... advanced imaging modalities for cardiology, showcased the first-ever HDi ... cases at the Transcatheter Cardiovascular Therapeutics meeting in ... from Medstar Washington Hospital Center ( Washington, D.C. ... ( New York, NY ). The HDi ...
(Date:9/17/2014)... 2014 , Glenmark,s ... positive data in a Phase 2a proof of concept ... Glenmark Pharmaceuticals today announced that its ... antagonist, GRC 17536 has shown positive data in a ... concept study conducted on 138 patients in ...
Breaking Medicine Technology:Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3ACIST Launches HDi High-Definition IVUS 2ACIST Launches HDi High-Definition IVUS 3Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3
... Md., July 13, 2011 When flu season arrives ... used anti-viral flu medication—will be available in a new, ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... Tamiflu. Oral suspension is a powder form of the ...
... 13, 2011 Chronic reflux patients who also suffer from ... visit to the operating room. MetroSouth Medical Center general surgeon ... Illinois to treat both conditions using a combination of laparoscopic ... an endoscope through the mouth to treat the reflux. In ...
Cached Medicine Technology:FDA CONSUMER HEALTH INFORMATION - Concentration Lowered in Tamiflu Medication 2MetroSouth Surgeon Pioneers Hybrid Treatment of Large Hiatal Hernias and Reflux 2
(Date:9/17/2014)... Dennis Thompson ... News) -- Twelve states now have confirmed cases of ... sickened hundreds of children, U.S. health officials report. ... New York, Oklahoma and Pennsylvania collectively have 130 laboratory-confirmed ... for Disease Control and Prevention. The virus, part ...
(Date:9/17/2014)... Rochelle, NY, September 17, 2014Diffusion Tensor Imaging (DTI), ... detects microstructural changes in brain tissue, can help ... outcomes following mild traumatic brain injury compared to ... according to a new study published in ... Mary Ann Liebert, Inc., publishers . The ...
(Date:9/17/2014)... out of the molecular therapeutic laboratory directed by Richard ... Women,s Oncology. Entitled "HE4 expression is associated with hormonal ... was recently published in the international science journal ... goal of the study was to investigate the role ... response to hormones and hormonal therapies. HE4 is a ...
(Date:9/17/2014)... 2014 For over a year now, ... data logging products to industries in Greece specializing in ... development of management systems for certification and accreditation. Main ... technical support. , MadgeTech Inc. is excited as ... are very pleased to see the success of Main ...
(Date:9/17/2014)... This news release is available in Spanish . ... overweight affect more than half of the population in ... organism, one of which affects liver function. Fat accumulates ... circumstances, causes inflammation, fibrosis and finally, cirrhosis. To date, ... been hepatic biopsy. Imaging techniques such as abdominal ecography ...
Breaking Medicine News(10 mins):Health News:12 States Now Reporting Severe Respiratory Illness That Targets Kids 2Health News:12 States Now Reporting Severe Respiratory Illness That Targets Kids 3Health News:New MRI technique helps clinicians better predict outcomes following mild traumatic brain injury 2Health News:Researchers examine role of hormone in response to ovarian cancer treatment 2Health News:Main Solutions Now Distributing MadgeTech Data Loggers in Bulgaria 2Health News:Magnetic resonance helps to detect and quantify fat in liver 2
... pediatric dermatologist explains prevalence of winter diaper rash and predicts ... COLLEGEVILLE, Pa., Dec. 2 /PRNewswire/ -- ... babies, the winter months can mean cute little red outfits, ... red bottoms. Most don,t think about their baby,s skin health ...
... Costs as Key , , WASHINGTON, ... Excellence report looks at how states are balancing retiree health care ... , Retiree Health Care in the American States ... care benefits to central human resources (HR) goals; how the states ...
... announced today the publication of Reproductive Health Matters ... abortion: women,s health and public policy". Second trimester ... burden on providers of service delivery and the sometimes ... issue of Reproductive Health Matters grew out ...
... N.J., Dec. 2 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp., ... fight infection and inflammation, announced today that its ... shareholder, The Westaim Corporation ("Westaim"), a requisition to ... a return of capital of US$0.80 per share ...
... Living Improves Service and Efficiency by Automating Access Management ... , FRAMINGHAM, Mass., Dec. 2 ... today announced that Brookdale Senior Living, the nation,s largest ... Courion,s Enterprise Provisioning Suite to deliver and manage secure ...
... Ind., Dec. 2 A number of recent public ... risks in,overweight children, and the questionable nutritional value of ... -- Funky Monkey(TM) Snacks,-- offers all natural, freeze-dried real ... kids, but also provide most, if not all, of ...
Cached Medicine News:Health News:Photos: Heads Up, Parents: Get to the Bottom of Winter Diaper Rash 2Health News:Photos: Heads Up, Parents: Get to the Bottom of Winter Diaper Rash 3Health News:Photos: Heads Up, Parents: Get to the Bottom of Winter Diaper Rash 4Health News:States View Limits on Retiree Health Benefits 2Health News:Elsevier announces the 2008 supplement of Reproductive Health Matters 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 3Health News:Courion Helps Reduce Costs at Nation's Largest Operator of Senior Living Communities 2Health News:Courion Helps Reduce Costs at Nation's Largest Operator of Senior Living Communities 3Health News:Moms Find Fun, Healthy Snacks That Help Fight Childhood Obesity 2Health News:Moms Find Fun, Healthy Snacks That Help Fight Childhood Obesity 3
This high technology cast plaster cutter saw is very easy and comfortable to use....
De Soutter supply clean cast removal saws that are low in voltage and contain an integrated extractor system, combining state-of-the-art ergonomics with performance and durability....
The Orengo staple is an oval staple, with thicker and longer legs (25 mm). It is then more especially bound to be used onto thick bones. The design of its stapler makes it more difficult to use und...
... VersaBond is a medium viscosity bone cement ... and shoulder implant fixation. VersaBond has superior ... for vacuum mixing, but can also be ... powder clumping. VersaBond meets customer needs by ...
Medicine Products: